Repeatability of bronchial responsiveness to mannitol dry powder in children with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 493s Year: 2001
The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
Bronchial hyperresponsiveness to dry powder mannitol and exercise test in adolescents with asthma Source: Annual Congress 2007 - Assessing asthma severity and control in children Year: 2007
Computerized measurements of inhalation ability with a dry powder inhaler in patients with severe COPD Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study Source: Eur Respir J 2011; 38: 1071-1080 Year: 2011
The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Handling and patient preference of dry powder inhalers for asthma and COPD Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
Numerical simulation of the effect of inhalation parameters and disease severity on the deposition of dry powder aerosol drugs in COPD patients Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD Source: Annual Congress 2012 - Hot topics in respiratory infections Year: 2012
Efficacy of two dosing schemes of a liquid containing ivy leaves dry extract EA 575 versus placebo in the treatment of acute bronchitis in adults Source: ERJ Open Res, 5 (4) 00019-2019; 10.1183/23120541.00019-2019 Year: 2019
Acceptability of two dry powder inhalers in 645 asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005
Efficacy of inhalation from different powder inhalators in COPD patiens with chronic respiratory failure Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
One-year height growth in children with asthma treated with inhaled budesonide delivered from a new dry powder inhaler. Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children Year: 2008
Systemic activity of two different dry powder combinations of inhaled corticosteroids and long-acting β2-agonists in children with asthma assessed by knemometry Source: Annual Congress 2012 - Assessing and treating childhood asthma and allergy Year: 2012
Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011
Efficacy of budesonide inhalation suspension in acute exacerbation of bronchial asthma in adults Source: Eur Respir J 2006; 28: Suppl. 50, 500s Year: 2006